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Evaluation of colorectal cancer subtypes and cell lines
using deep learning
Jonathan Ronen1,2 , Sikander Hayat3, Altuna Akalin1
Colorectal cancer (CRC) is a common cancer with a high mortality
rate and a rising incidence rate in the developed world. Molecular
profiling techniques have been used to better understand the
variability between tumors and disease models such as cell lines.
To maximize the translatability and clinical relevance of in vitro
studies, the selection of optimal cancer models is imperative. We
have developed a deep learning–based method to measure the
similarity between CRC tumors and disease models such as
cancer cell lines. Our method efficiently leverages multiomics
data sets containing copy number alterations, gene expression,
and point mutations and learns latent factors that describe data
in lower dimensions. These latent factors represent the patterns
that are clinically relevant and explain the variability ofmolecular
profiles across tumors and cell lines. Using these, we propose
refined CRC subtypes and provide best-matching cell lines to
different subtypes. These findings are relevant to patient strat-
ification and selection of cell lines for early-stage drug discovery
pipelines, biomarker discovery, and target identification.
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Introduction
Colorectal cancer (CRC) accounts for 10% of cancer-related deaths
(1), with ~1.4 million new cases and 693,900 deaths reported in 2012
(2). CRC is not homogeneous and can be classified into different
subtypes based on molecular and morphological alterations (3).
The disease occurs when normal epithelial cells acquire genetic
and epigenetic alterations that transform them to cancer cells.
Mutations in the WNT signaling pathway are thought to initiate the
transformation to cancer (4, 5). This is followed by deregulation of
other signaling pathways such as MAPK, TGF-β, and PI3K–AKT via
acquired mutations (5, 6). Since the original description of the mo-
lecular pathogenesis of CRC, multiple additional pathways, mutations,
and epigenetic changes have been implicated in the formation of CRC
(7). Based on integrative analysis of genomic aberrations observed
in The Cancer Genome Atlas (TCGA) samples, a distinction can
be made between hypermutated (≈16%) and non-hypermutated
(≈84%) CRC. The hypermutated cancers exhibit microsatellite
instability (MSI), resulting from defective mismatch repair or DNA
polymerase proofreading mutations (3). Non-hypermutated micro-
satellite stable (MSS) cancers are characterized by chromosomal in-
stability (CIN), withhighoccurrenceofDNAcopynumber alterations and
mutations in the APC, TP53, KRAS, and BRAF genes (3). Most CRC
tumors have aberrantly methylated genes, a subset of which may
play functional roles in CRC (7). A further subset of CRC tumors
display a CpG island methylator phenotype (CIMP), in which some
tumor suppressor genes may be epigenetically inactivated (8). The
diversity of molecular disease mechanisms results in distinct mo-
lecular subtypes of CRC, associated with different survival rates and
responses to therapy. Hence, molecular subtypes can provide more
clinically relevant information than standardised tumor staging based
on the size andmetastasis. A number ofmolecular subtyping schemes
based on gene expression profiles were recently studied and sum-
marized as the consensus molecular subtypes (CMS) (9), designating
four main CRC subtypes with distinguishing features. The CMS1
subtype is defined by hypermutation, MSI, and strong immune
activation; CMS2 is defined by CIN, WNT, and MYC signaling acti-
vation; CMS3 is defined by metabolic dysregulation; and CMS4 is
defined by growth factor β activation, stromal invasion, and an-
giogenesis (9). This leaves ~13% of the tumors that cannot be
assigned to a consensus subtype, as they have mixed gene ex-
pression signatures. These may represent distinct tumor subtypes
or samples with intratumor heterogeneity. The CMS classification is
based on gene expression, yet follow-up analysis of the tumors
revealed distinct copy number profiles, mutation frequencies, and
methylation profiles (9) (Fig S6), indicating that much can be gained
from integrating other types of omics data.
We propose a multiomics method that incorporates data on
gene expression, copy number, and mutations in identifying CRC
subtypes, in a manner that has important implications for patient
stratification. Our method is able to match cell lines to each subtype,
and in the future, it will be useful in assigning best-matching
xenografts or organoid models to the study of each subtype. Patient-
derived tumor models have been shown to predict in patients’ re-
sponse to treatments (10), and so by finding best-matching tumor
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models, we hope to empower their clinical use without the need to
grow new organoids from each patient. Using multiomics data sets
permits subtyping of CRC tumors that have not been associated with a
CMS subtype, which is based on gene expression only. The multiomics
signatures, incorporating gene expression, point mutations, and copy
number alterations, are a direct output of themethod and do not need
to be generated post hoc, for example, by examining mutation rates in
groups defined by gene expression profiles, as is the case with CMS.
With these goals in mind, we used deep learning onmultiomics data to
refine CRC subtypes in an unsupervised manner and then match them
to cell lines.
Genomic assays are high dimensional (tens of thousands of genes),
and high-dimensional spaces are challenging to analyze. This
problem is further exacerbated when seeking to integrate mul-
tiple types of assays from diverse omics platforms. It is, therefore,
beneficial to introduce methods which are able to recognize pat-
terns in the molecular signatures spanning different omics data
types. Latent factor analysis is an unsupervised learning technique
well suited to the task at hand. This type of analysis is sometimes
referred to as dimensionality reduction; it seeks to learn (infer) a
lower dimension representation of data, which preserves the im-
portant structure/pattern therein. The method describes data
using a handful of latent factors, rather than tens of thousands of
genes, simplifying downstream analysis such as distance calcu-
lations and clustering (11). In the context of multiomics data
analysis, latent factors may be thought of as high-order genomic
features. Instead of examining point mutations or expression values
of single genes, latent factors summarize patterns that span different
data types.
The patterns represented by latent factors should be in-
terpretable in the biological context, that is, it is desirable that the
patterns correspond to cellular processes. Matrix factorization
has become the workhorse for latent factor analysis for multio-
mics and general data analysis (12). Latent factor analysis for
multiomics data typically includes concatenating different omics
data to a single matrix and applying a well-known matrix fac-
torization algorithm, sometimes with weighting of the individual
data sets. Multifactor analysis (MFA) (13) and iCluster+ (14) are
examples of such methods. Some such algorithms, such as MFA,
impose orthogonality of factors, that is, the factors explain dis-
joint underlying processes, as in PCA. Orthogonality might be
conceptually appealing, but is not a biological necessity. Or-
thogonal latent factors may be the best for statistical re-
construction of a data set and still be biologically difficult to
interpret. On the other end of the spectrum, deep learning–based
methods work as dimensionality reduction techniques that can
deal with nonlinearity and can generalize well on a number of
problems. In addition, they can be sparse: each latent factor
depends only on a few of the input genes, and each tumor is
described by only a handful of latent factors. This sparsity sim-
plifies the task of biological interpretation of the model by
pointing out specific biological processes underlying the latent
factors; conversely, sparsity in the relationship between latent
factors and tumors simplifies downstream analyses such as
clustering.
Although it is reasonable to expect that the latent factors de-
scribing the data be of much lower dimensionality than the
genome-scale input data, it is an open question just how low the
dimensionality should be. Heuristics to pick the number of latent
factors have been proposed by method designers. PCA and MFA
typically suggest an elbow method, where latent factors are
ordered by their variance explained, and the user determines an
elbow point in the graph, discarding latent factors with a low
variance explained. MOFA formalizes this heuristic by starting the
fitting process with a high number of latent factors, and during
training, discarding ones with a variance explained below a preset
threshold (with a default value of 2%). iCluster+’s heuristic comes
from its k-means roots, that is, one tends to set the number of
latent factors to K − 1, where K is the number of clusters one
expects to find. Recently, a large-scale study of latent factor
methods (15 Preprint) has demonstrated the desirability of
specifying more latent factors than are expected to exist in the
data. Specifically, it was shown that using more latent factors than
are needed can compensate for shortcomings in the training
algorithm and improve log-likelihood and recovery of ground
truth latent factors. Hence, it is desirable to have a latent factor
method that is able to learn a large number of latent factors
efficiently from data.
With these requirements in mind, we used a variational autoen-
coder (VAE) (16 Preprint), a flexible framework for nonlinear latent
factor inference. Our implementation is inspired by methods imple-
mented by ladder-VAE (17 Preprint) and disentangled autoencoders
(β-VAE) (18). Using these adaptations over a “vanilla” VAE enables the
model to converge quickly to a good representation, in spite of the
seemingly large complexity of the problem space. Such deep learning
frameworks are flexible and have been used to deal with many kinds
of data sets (19 Preprint). A similar method proved successful at
stratifying cancers by their tissue type based on gene expression
profiles (20 Preprint), and other autoencoder architectures have
been used to integrate multimodal data in robotics (21), as well as
protein function prediction (22).
Here, we used a multimodal, stacked VAE to extract latent factors
that can be used to identify CRC subtypes and predict patient
survival. We call the method, “multiomics autoencoder integration,”
or maui. We compared maui performance with state-of-the-art
multiomics analysis methods and showed that it outperforms
the matrix factorization methods, showing improved clinical rele-
vance. Computationally, maui’s is in orders of magnitude more
efficient than the state-of-the-art methods we compared it with. In
a further step, we map commonly used CRC cell lines to the latent
factor space defined by maui. This allows us to use patterns rec-
ognized by maui as significant in CRC to rank the suitability of in
vitro models for the study of specific tumors. We, then, determined
the cancer cell lines most appropriate for drug target studies aimed
at distinct CRC subtypes.
Results
Refining CRC subtypes using multiomics data
The CRC cohort in the TCGA data set (n = 519, see the Materials and
Methods section) has been extensively studied. Statistical analysis
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supports the use of clinical follow-up data (23), and a state-of-the-
art subtyping scheme is described in the “consensus molecular
subtypes” for CRC or CMS (9) (Table 1). To validate the relevance of
latent factors learned by maui to cancer biology, we tested the
extent to which these latent factors recapitulate the known
subtypes.
We used maui to extract latent factors from data on gene ex-
pression, point mutations, and copy number alterations and did
the same using MOFA (24) and iCluster+ (14), other published
methods for multiomics integration by dimensionality reduction.
We also used PCA as a baseline for integrating multiomics data
(see the Materials and Methods section). We based our com-
parison of the methods on a quantification of the relationship
between latent factor representations and the CMS subtype, using
support vector machines (SVMs) to predict the CMS subtype from
the latent factor representation. We used regularized linear SVM,
where the regularization parameter was selected using cross-
validation (CV). Also using CV, we predicted the CMS label of each
tumor out-of-sample (when it was in the validation fold, see the
Materials and Methods section). We then computed “receiver
operating characteristics” (ROCs) and the area under the curve
(see the Materials and Methods section). The area under the ROC
(auROC) is a measure of classification accuracy. A random guess is
expected to deliver a score of 0.5, and 1.0 would represent perfect
prediction. All three methods produce latent factors with pre-
dictive power of the CMS labels above random guessing (Figs 1A
and S1A). Using the SVM, maui (auROC 0.98) marginally out-
performs MOFA (auROC 0.94), and both dramatically outperform
iCluster+ (auROC 0.73) and PCA (auRoc 0.85) (Figs 1B, S1B, and S2).
In this analysis, maui had an advantage over MOFA, in that it was
run with 80 latent factors, whereas MOFA only generated 20 (MOFA
uses heuristics to pick the number of latent factors). Supervised
learning algorithms such as SVM may benefit from a larger
number of input features (here, the latent factors). We would like
to demonstrate that maui’s ability to learn more latent factors
(owing to its superior computational efficiency) is beneficial in a
fair benchmark. To assess which of the methods is best able to
capture the CMS labels, regardless of the number of latent factors,
we repeated the previous exercise—predicting the CMS from the
latent factors—using an unsupervised learning algorithm. We
clustered the samples with a well-defined CMS (some CRC sam-
ples do not have a CMS) using k-means clustering on the latent
factors (see the Materials and Methods section). We let K to vary
from 2 to 9, and for each K, we computed adjusted mutual in-
formation (AMI) of the clustering with the CMS labels. k-means
clustering only reproduces the CMS subtype to a significant de-
gree for K values of 4–6 only using maui (Figs 1C and S1C). This
analysis shows that maui factors are superior at predicting CMS
labels, in a fair comparison, as k-means clustering is based on dis-
tances, whose computation does not benefit from higher dimensio-
nality—in fact, the opposite is true (11).
Latent factors inferred by maui are predictive of the CMS subtype
using k-means, especially using K’s 4–6 (Fig 1C). To pick the best
clustering result to focus on, we computed the log-rank statistic for
the significance of the differential survival rates between clusters
(see the Materials and Methods section). K = 6 results in the most
statistically significant survival difference (P < 0.001, Figs 1D and
S3C). Note that the CMS subtypes on their own are not indicative of
survival rates in the TCGA data (P = 0.77 Fig S3A) and that K = 4 (P <
0.045 Fig S3D) and K = 5 (P < 0.019 Fig S3B) also produce clusters
with significant differential survival rates. Notably, K = 6 is
preferable to K = 4 and K = 5, as it is able to tease out a cluster of
patients with particularly poor prognoses (cluster 3); this con-
sists mainly of a subset of tumors designated as CMS2 (canonical)
(Fig S3). K-means clustering of MOFA or iCluster+ latent factors
do not produce statistically significantly separable clusters (Figs
S4 and S5).
We also compared the ability of maui, MOFA, and iCluster+ to
predict patient survival, irrespective of any clustering. For each
model, we first selected a subset of latent factors which are
individually predictive of patient survival, calling those clinically
relevant latent factors. This was carried out by fitting univariate
Cox proportional hazards regression models, one per latent
factor, and selecting ones for which the coefficient is nonzero
with P < 0.05 (see the Materials and Methods section). Using
those clinically relevant latent factors, we fitted a multivariate
Cox proportional hazards regression and computed Harrell’s
c-index (25) (see the Materials and Methods section). The c-index
is a measure of prediction accuracy for censored data, with a
score of 0.5 expected for random guessing and 1.0 representing
perfect accuracy. maui (c = 0.72) outperforms MOFA (c = 0.68),
iCluster+ (c = 0.64), and PCA (c = 0.64) in this benchmark (Figs 1E
and S1D).
The CMS subtyping scheme, as well as much of the work in the
field, is based solely on gene expression profiles. To examine
whether maui gives better predictions of patient survival with the
addition of mutations and copy number data, we also trained a
maui model based on gene expression alone. The maui model
based on expression alone (c = 0.69) achieves a lower score than a
maui model with multiomics data (c = 0.72), even when the former is
provided with more genes as input features (Fig 1F). This indicates
that data other than transcriptomes do contribute to overall
performance of maui.
One advantage of maui over other methods such as iCluster+
and MOFA is that it is able to learn orders of magnitude for more
latent factors, at a fraction of the computation time (Table 2). To
demonstrate the advantage of being able to fit larger models, we
also trained a maui model based on 6,000 multiomics features
(see the Materials and Methods section). That model (c = 0.75)
outperforms the smaller model (Fig 1F), demonstrating the
Table 1. Summary of TCGA tumors’ CMS labels.
CMS label Description No. of samples
CMS1 MSI immune 61
CMS2 Canonical 175
CMS3 Metabolic 60
CMS4 Mesenchymal 123
Total with CMS label 419
Without CMS label 100
Total 519
Bold entries indicate sums.
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clinical utility of learning frommore input features and underlining
the importance of the computational efficiency offered by
maui.
Finally, we investigated the usefulness for CRC subtyping of using
prior information from protein interaction networks. Several groups,
including our own, have previously incorporated gene–gene in-
teractions using a method called network smoothing (26, 27). This is
accomplished by allowing binary mutation values to diffuse over a
gene network, a process which assigns nonzero “mutation scores”
rather than binary mutation values, to genes which either have
mutations or interact with mutated genes. To carry this out, we
used a gene network defining interactions between genes from
the STRING db (28), a database of protein–protein interactions. We
applied the netSmooth (27) algorithm (see the Materials and
Figure 1. maui, MOFA, iCluster+, and the CMS labels.
(A) UMAP (29) reduced dimensions from latent factors inferred by maui, MOFA, and iCluster+. Each dot represents a tumor, colored by their CMS label. (B) ROCs for
regularized SVMs predicting the CMS label from latent factors (out-of-sample, 10-fold CV). Mean ROC shown (see the Materials and Methods section) (C) The AMI (see the
Materials and Methods section) of clusters obtained from latent factors inferred by maui, MOFA, and iCluster+, using k-means clustering with K ranging from 2 to 9.
(D) Kaplan–Meier estimates and the log-rank statistic for differential survival of different clusters. The reported P value is from a multivariate log-rank test, under the
null hypothesis that all groups have the same survival function. Clusters 3 and 5 represent a novel splitting of a previously defined subtype, CMS2. (E) Harrell’s c-index for
Cox regressions of iCluster+, MOFA, and maui shows maui is more predictive of patient survival than other methods. (F) Harrell’s c-index comparing different maui flavors
shows that maui benefits from multiomics data, as well as from more input genes. (G) Harrell’s c-index shows network smoothing of mutations improves survival
prediction using maui.
Cancer multiomics with deep learning Ronen et al. https://doi.org/10.26508/lsa.201900517 vol 2 | no 6 | e201900517 4 of 16
Methods section) to the mutation data before passing it to maui
and computed Harrell’s c-index, as above. This revealed that
network smoothing mutations further improve the clinical rel-
evance of latent factors learned when integrating multiomics
data (c = 0.79) (Fig 1G). Other network sources than STRING db, or
protein–protein interactomes (PPIs) in general, also result in
improvements using netSmooth, whereas networks with similar
characteristics but without real information about interactions
do not (27).
A closer examination reveals the degree to which maui clusters
resemble the CMS subtypes and where they diverge. CMS1 is
captured by cluster 2, CMS2 is split between clusters 3 and 5, CMS3 is
captured by cluster 0, CMS4 overlaps with cluster 4, and cluster 1 is
mixed (Fig 2A–C). A similar conclusion can be reached based on a
set of molecular indicators introduced in (9): CMS1 and cluster 2
show the hypermutated (Fig S6A), CIMP (Fig S6B), and microsatellite
unstable phenotypes (Fig S6C). They also exhibit similar mutation
rates among TP53, APC, KRAS, and BRAF (Fig S6D), a set of genes
commonly mutated in CRCs.
This might explain a seeming contradiction in the results—maui
clusters, which are predictive of patient survival (Fig 1D), largely
recapitulate the CMS, which is not predictive of survival in this
cohort (Fig S3A). This is possible because although there is much
agreement between maui and the CMS, there are small discrep-
ancies in each cluster (Fig 2C). The CMS subtypes were defined
based on gene expression signatures alone, using a larger cohort of
patients which also includes the TCGA cohort, used here. The larger
cohort, however, does not have multiomics data, and so we were
unable to test this result in the larger cohort (in which the CMS is
predictive of survival).
Fig 2C and S6 beg the question of why CMS2 was split into two
clusters (3 and 5). To investigate the biological plausibility of this
distinction, we performed a differential expression analysis and
identified marker genes for each cluster. We, then, ran these lists
through a gene set enrichment analysis (see the Materials and
Methods section). Eachmaui cluster turns out to be associated with
a distinct set of pathways (Fig 2D). Specifically, cluster 3 is domi-
nated by TGF-β signaling and leukocyte migration, whereas cluster
5 is dysregulated in ErbB, Hippo, and Wnt signaling pathways. These
findings demonstrate that groups are distinct and exhibit different
molecular phenotypes. Further evidence comes from the fact that
prognoses for patients in cluster 3 are worse than cluster 5 (log-
rank P < 0.001, Fig S7). Cluster 4 (CMS4) is enriched in pathways
associated withmobility and structural differences (Fig 2D), which is
consistent with the higher stromal infiltration found in patients
with CMS4 (9).
CRC latent factors are associated with processes related to tumor
progression and development
The superior computational efficiency of maui enables it to infer a
large number of latent factors frommultiomics data. This provides an
opportunity to select those that are most interesting andmight serve
as biomarkers. To demonstrate this, we fitted Cox proportional
hazards models (29), fitting one regression model for each factor, as
above, selecting clinically relevant latent factors (see the Materials
and Methods section). Fig 3B shows the 95% confidence interval of
coefficients for these latent factors, showing that high values for
some of these latent factors are predictive of a poor prognosis (β > 0),
whereas others are predictive of more favorable outcomes (β < 0).
This lends a significant prognostic value to such latent factors.
Another use derives from an interpretation of what these bio-
markers represent. maui is very powerful because it can learn
highly nonlinear patterns. This comes at a certain cost: it makes the
biological interpretation of factors less straightforward than in a
linear matrix factorization approach, such as PCA or MOFA. These
other methods learn linear relationships between genes and latent
factors, of the form x =Wz, whereW is directly available. FromW, the
connections between latent factors and genesmay be directly read.
maui does not produce a straightforward, linear W, so to associate
latent factors with input genes, we correlated input genes with
latent factor values (see the Materials and Methods section). While
most latent factors are active in the gene expression domain,
mutation data do not significantly affect most of them. Some latent
factors capture interactions between two or more omics types (Fig
3A). This correlation between latent factors and input features
permits us to overcome the difficulties presented by the nonlinear
relationships and use the associations to find biologically relevant
interpretations for the neural latent factors.
When we associated clinically relevant (see the Materials and
Methods section) latent factors with gene ids, we observed an en-
richment of pathways such as Wnt signaling and other APC-mediated
processes known to play a role in CRC (Fig 3C). One of the factorsmost
significantly associated with survival is enriched in neuronal growth
factor (NGF) signaling. NGF signaling, which controls neurogenesis,
has been associated with aggressive colorectal tumors (30, 31). Other
latent factors relevant to survival implicate PDGF signaling, which is
associatedwith stromal invasion and poor prognosis for CRC patients
(32, 33). Thus, in addition to exposing latent factor biomarkers with
the prognostic value, maui sheds light on underlying biological
processes that merit study in search for new drug targets.
maui performance is robust to parameter choice
To check the robustness of maui and ensure we were not over-
fitting, we ran maui and iCluster+ with a range of parameters, such
as the number of latent factors. MOFA uses a heuristic to pick the
number of latent factors, starting with a large number, and during
training, removing latent factors which explain the variance in the
data below a threshold of 2%.
Table 2. Summary of methods.
Method Notes No. offactors Runtime
iCluster+ Bayesian, MCMC 10 ~11 h
MOFA Bayesian, variational 20 20 min
maui Multilevel Bayesian, StochasticGradient Descent 100 3 min
Reported runtimes are on a single core of an Intel(R) Core(TM) i7-7500U CPU
@ 2.70 GHz, on an HP Spectre x360 laptop with 16 GB of ram. No graphics
processing units were used to fit the neural network.
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We designed a compound benchmark score to test the
overall performance of the model (see the Model selection
section). We computed the compound benchmark score for
each model using the different hyperparameter sets (see the
Materials and Methods section). maui robustly outperforms
iCluster+ (P < 0.001, one-sided t test) and MOFA (P < 0.01, one-
sided t test) (Fig S11).
Quality assessment of CRC cell lines as models for tumors
The molecular profiles of cancer cell lines often differ signifi-
cantly from those of tumors because of the differences in se-
lective pressures faced by cells in culture and natural tumor
microenvironments; adaptation requires distinct genomic al-
terations (34). This means that not all colorectal-derived cancer
Figure 2. Clustering the tumors using k-means using the latent factors frommaui reproduces the CMS labels closely, with the exception of CMS2 being split into two
clusters, 3 and 5.
(A, B, C) UMAP embedding of tumors colored by the CMS label, (B) UMAP embedding colored by k-means clusters on maui latent factors. (C) Cluster diagram depicts the
correspondence betweenmaui clusters and the CMS subtypes: the two rows represent the different labeling schemes (maui clusters and CMS subtypes), and each column
represents a sample, which is colored according to its assignment in each row. The legend in subfigures (A, B) applies to the color scheme in (C) as well. (D) Pathways
that are enriched in differentially expressed genes for each maui cluster. Clusters show a disjoint set of dysregulated pathways, underlining the different molecular
phenotypes which underlie each group. Cluster 3 and 5 (which togethermake up the bulk of CMS2) are dominated by dysregulation of TGF-β signaling and ErbB/Wnt/Hippo
signaling, respectively.
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cell lines are likely to have equal value as models for tumors.
Furthermore, over time, cancer cell lines run the risk of con-
tamination and mislabeling. For instance, a cell line which was
originally annotated as colorectal has been shown to be derived
from melanoma (35). Because the identification and quality
control of the cell lines are crucial steps in the research process, it
is essential to know if the lines have diverged too much from
tumors in their molecular makeup, been mislabeled, or contami-
nated. We examined 54 cancer cell lines derived from tumors of the
colon from the Cancer Cell Line Encyclopedia (CCLE). We used maui to
infer latent factor values for the cell lines to permit their character-
ization using the same latent factors as the tumors. As cell lines may
develop adaptations specific to cell culture, their molecular profiles
are often more similar to other cell lines than to those of primary
tumors. We, therefore, hypothesized that cancer cell lines that are
more similar to other cell lines than to tumors are less likely to be
appropriate models for CRC tumors. We compiled a list of nearest
neighbors (see the Materials andMethods section) for each cell line
and, then, counted how many of its nearest neighbors are cell lines
(as opposed to tumors). We used Euclidean distance in the space
defined by the latent factors to determine similarity and found that
about half of the CRC cell lines we investigated belong to a “cell line
cluster,” meaning that most of their neighbors were other cell lines
(Fig 4A). We eliminated cell lines where this proportion is above half
and found among them a mislabeled cell line: COLO741, which has
been shown to derive from melanoma and not from CRC (in more
recent versions of the CCLE annotations, this has been fixed). This
finding indicates the merit of using this method to flag cell lines as
poor models for tumors.
In lieu of` knowledgeof othermislabeledor otherwise inappropriate
colon-derived cancer cell lines, we artificially contaminated the data
set by adding a random sample of 60 noncolon cell lines, assuming
that these would be ill suited to the study of CRC tumors. The
identities of these “known contaminant” cell lines are irrelevant,
as we show later that the method works on 100 such random
draws. We used this to repeat the exercise of counting the
nearest neighboring cell lines. With the introduction of these
true positives (non-colon cancer cell lines are considered true
positives in the task of predicting which cell lines are poor
models for CRC tumors), we found that more of the cell lines could
be assigned to a “cell line cluster” in which most of their neighbors are
other cell lines (Fig 4B). For nearly all noncolon derived cell lines, the
Figure 3. Interpretation of maui latent factors.
(A) A heatmap depicting the absolute correlation coefficients of the different input genes with the latent factors. Only input features with significant correlations (Padj <
0.01, see the Materials and Methods section) are depicted in the heatmap. The row annotation shows the type of input feature, that is, expression value, mutation, or copy
number. (B) The coefficients in a Cox proportional hazards regression for factors which are clinically relevant (*) when controlling for patient age, sex, and tumor stage.
Coefficients also shown for those covariates. (C) Pathway enrichment scores for genes associated with the latent factors which carry the prognostic value (have
significant effects in Cox regression). (*) Clinically relevant factors are factors with a coefficient in a fitted Cox model controlling for age, sex, and tumor stage, which are
statistically significantly nonzero (Padj < 0.05).
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five nearest neighbors were other cell lines, whereas this was not
the case for colon-derived cell lines (Fig 4C). As a result, we
designated cell lines whose five nearest neighbors are other
cell lines, as less suitable for the study of colorectal tumors
(“rejected”), as they more closely resemble other cell lines, even
those derived from other tissues. We retain cell lines with at least
one tumor among their five nearest neighbors as more likely to be
suitable models. The choice of K = 5 for the number of nearest
neighbors is immaterial, as the method is insensitive to the choice of
K (Fig S8). UMAP embedding of the latent factor space of tumors (with
CMS labels, n = 419), CRC cell lines (n = 54), and noncolorectal (ar-
tificial contamination, n = 60) cancer cell lines shows that this
procedure eliminates most contamination cell lines, as well as some
of the colon cancer cell lines, and that nonrejected cell lines are
spread among all clusters (Fig 4D). Although, we advise caution when
interpreting Fig 4D. The distances in 2D plot are not fully repre-
sentative of the Euclidian distances and can be misleading as some
cell lines look like rejected but they are near primary tumors in 2D.
However, these cell lines are not near primary tumors when higher
dimensions considered. We repeated the analysis with 100 more
randomdraws of 60 additional contaminants. For each such draw, we
rejected any cell line whose five nearest neighbors are cell lines. This
method consistently rejects almost all known contaminants and
about half of the CRC cell lines (Fig 4E). Rejecting these cell lines is not
necessarily a mistake because even if they originate in colon cancer, this
does not guarantee they will be good genomic models for such
tumors because of, for example, genomic divergence, mislabeling,
or contamination. In addition, the fact that a particular cell line
more closely resembles noncolon-derived cancer cell lines than CRC
tumors is an indication that it might not be suitable as a model for CRCs.
That this method successfully rejects almost all known contaminants is
another indication that rejected colon cancer cell lines are likely to be
poor models for CRC as well. The CRC cell lines CL40, SW1417, and
CW2 are deemed most suitable as models for CRC tumors (Fig 5).
Using the same criteria, the cell line COLO320 ranked among the
lowest. COLO320 lacks mutations in major CRC driver genes such
as BRAF, KRAS, PIK3CA, and PTEN, and it is actually of a neuro-
endocrine origin (36, 37). This very likely makes COLO320 a poor
model for CRC.
Figure 4. For each cell line, we compiled a list of five nearest neighbors in latent factor space and counted the nearest neighbors that are cell lines (as opposed to
tumors).
Cell lines whose five nearest neighbors are all other cell lines are marked as less likely to be appropriate models for tumors, as they are more similar to cell lines than to
tumors. Cell lines that had at least one nearest neighbor that is a primary tumor (not a cell line) were marked as likely goodmodels. The nearest neighbors were calculated
using the Euclidean distance in the space defined by the latent factors. Subfigure (D) above (UMAP projection of the latent factor space) does not always reflect the
nearest neighbors, as UMAP gives no such guarantees. (A) Histogram of the proportion of nearest neighbors of cell lines which are also cell lines, CRCs only. (B) Histogram
of the proportion of nearest neighbors of cell lines which are also cell lines, CRCs, and noncolorectal cell lines (C) Kernel Density Estimates of the proportion of cell-line
neighbors among all cell lines (colorectal and noncolorectal), broken down by tissue. (D)UMAP embedding of tumors and cell lines. Crosses are colon-derived cell lines;
diamonds are artificial contamination (noncolon-derived cancer cell lines). Red cell lines are rejected, and black ones are retained as more likely to be good models.
(E) The proportions of colon and noncolon cell lines which are rejected because their proportion of nearest neighbor cell lines is above the threshold. Nearly all noncolon
cell lines are consistently rejected, as well as about half of the colon cell lines.
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A complete subtyping scheme for CRC and appropriate cell lines
for the study of each subtype
The CMS scheme (9) is incomplete because it is unable to classify
many tumors. We used maui to assign the remaining non-CMS tu-
mors to subtypes by repeating the clustering analysis while including
both tumors that do not have a CMS designation and cancer cell
lines. In this process, we included the cancer cell lines deemed to be
suitable models (see above) to assign the cell lines to CRC subtypes.
Here, we present a novel subtyping scheme for CRC, which covers the
whole TCGA cohort and includes tumors without a CMS designation.
We also associate CRC cell lines with these subtypes. The tumors
without a CMS label are distributed roughly according to the cluster
size, as is to be expected for samples that lack a consensus definition
(Fig 6A and B), and each cluster is associated with at least one cell
line (Fig 6C and Table 3). The correspondence between our clusters
and the CMS subtypes remains strong also when including cell lines
and non-CMS tumors (Fig 6D). Cluster 2 (CMS1, MSI) is associated with
the most cell lines; it comprises hypermutated tumors with low CIN.
The cell lines thatmatched to cluster 2 show the same characteristics
(Fig S9), another indication that latent factors capture patterns which
are important to cancer biology. We believe that both the new
Figure 5. For all colon-derived cell lines, we compiled
lists of their five nearest neighbors.
The barplot shows how many of those five were other
cell lines. Cell lines where all five nearest neighbors are
other cell lines are rejected, those having at least one
nearest neighbor that is a tumor are kept and assigned
to clusters, as shown in the table on the right.
Figure 6. Assignment of non-CMS tumors and cancer
cell lines to clusters. (A) The sizes (number of
samples) of the clusters. (B) The number of non-CMS
tumors assigned to each cluster. (C) The number of
cancer cell lines associated with each cluster. (D)
Cluster diagram depicts the correspondence between
maui clusters and the CMS subtypes: the two rows
represent the different labeling schemes (maui
clusters and CMS subtypes), and each column
represents a sample, which is colored according to its
assignment in each row. The NOLBL samples without
a defined CMS subtype are distributed among all
clusters, as are cancer cell lines CCLE.
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classification system and the assignment of best-fitting model cell
lines will be a useful resource for future drug discovery studies in
CRCs.
Discussion
CRC is a heterogeneous disease, with subtypes that are driven by
different types of genomic alterations: hypermutated tumors, tumors
showing CIN, etc. Multiomics data analysis has the potential to clarify
questions regarding disease subtypes. Taking advantage of this will
require new methods which scale computationally as the amount of
available data increases. In addition to stratifying patients into clin-
ically relevant subgroups, it is necessary to find potential drug targets
specific to each subtype.Most drug target discovery studies use cancer
models such as cell lines, organoids, or xenografts, and it is thus
necessary tomatch these cancermodels to the appropriate subtype in
each study, or if a cancer model is inappropriate for the study of any
subtype, to be able to flag it as such.
We have developed an autoencoder-based method, called maui,
that integrates data from multiomics experiments. We used it to
infer latent factors that summarize molecular patterns, from data
sets made up of RNA-seq, single nucleotide polymorphisms, and
copy number variants (CNVs). The latent factors capture patterns
which explain the variation across the different data modalities,
capturing important aspects of cancer biology including different
gene expression programs, mutational profiles, copy number pro-
files, and their interactions. We showed that these latent factors are
predictive of previously described CRC subtypes (CMS). maui out-
performs the methods MOFA and iCluster+, which we benchmarked
against in the task of CMS label prediction and in predicting patient
survival regardless of the CMS subtypes involved. From the stand-
point of computational performance, maui can extract more latent
factors from larger data sets at a fraction of the computational cost
of both iCluster+ and MOFA, making it better suited for the analysis
of increasingly larger data sets. It can leverage its computational
efficiency to learn from larger data sets, containing more genes, to
produce latent factors which aremore predictive of patient survival;
using 6,000 genes, maui produces more clinically relevant repre-
sentations than using 1,300 genes. We also used these latent factors
to produce a novel system of classification for CRC. In addition to
reproducing the CMS nearly perfectly, it revealed that one of the CMS
subtypes, CMS2, is in fact two distinct tumor subtypes. These have
different characteristics in terms of the underlying gene expression
programs and distinct survival rates. This shows that the prognostic
value is improved by an unbiased selection of more input genes,
rather than restriction to known markers or driver mutations. Our
results support the idea that passenger mutations and driver mu-
tations could have an effect on cancer outcomes (38).
iCluster+, which we compared with maui in the first part of this
study, is already strained at 1,300 input genes (runtime of 11 h), and in
the future, with even more data types (e.g., methylation), we expect
the input spaces to grow far beyond 6,000 that were used here. We
still recommend that users of maui who are interested in using, for
example, DNA methylation data perform some feature selection on
the 450,000 or so CpG’s, in a similar way to the feature selection we
performed on gene expression, mutation, and copy number data.
Hence, the computational efficiency of maui is not a mere academic
exercise; at today’s scale, this increase in computational efficiency is
the difference between a model that can be fit at all and one which
cannot. In addition to using more input features, the computational
efficiency allows maui to learn more latent factors than we might
believe to truly exist in the data. This is desirable in latent factor
models, as fittingmore latent factors increases the amount of ground
truth factors which are recovered by a method. This effect tends to
outweigh any harm that may come from overparameterizing the
model (15 Preprint). By example, ranking latent factors by their
clinical relevance (as in Fig 3B), we have shown that we can fish out
the ground truth latent factors from a potentially overparameterized
model. So here too, the computational efficiency premium offered by
maui over iCluster+ and MOFA comes with real-world benefits.
Individual latent factors have prognostic relevance. They can
also be associated with genes. A pathway analysis of the latent
factors that are most predictive of patient survival revealed an
enrichment of known CRC-related pathways, such as Wnt signaling
and other APC-mediated processes, NGF signaling, and PDGF sig-
naling (39). Although the association between latent factors and
individual genes is not as straightforward with maui as using matrix
factorization methods, the pathways it reveal are informative. We
also propose a way to use latent factors learned by maui to predict
the overall fitness of specific cancer cell lines asmodels for CRC and
specific subtypes of the disease. We hypothesized that cell lines
which bore a higher resemblance to other cell lines than to CRC
tumors would serve as poorer models. To test this, we included
non-CRC cell lines in the sample. By testing whether a cell line is
more similar to other (noncolon) cell lines or CRC tumors, we
correctly identified 98% of non-CRC cell lines, which are very likely
to be poor models for CRC. In addition, ~45% of CRC cell lines were
predicted to be poor models for CRC, including COLO741 and
COLO320, which are known to be inappropriate (35, 36, 37). These
conclusions will need to be validated by further experiments. Al-
though cell lines that were predicted to be less appropriate for the
study or CRC may still be helpful in studying, for example, genetic
interactions, their utility in studies of, for example, adaptive drug
response may be limited. On the other hand, the SW480 and SW620
cell lines are predicted to be a good match for CRC, and they have
shown similar drug response to clinical trials on KRAS mutant
tumors (40).
Table 3. maui clusters and the cancer cell lines associated with them.
Cluster Description Cell lines
0 CMS3(metabolic)
SW948, CL14, SNU1197, RCM1, NCIH508, CL40,
T84, SKCO1
1 Mixed type SNU283, MDST8
2 CMS1 (msi,immune)
CW2, HT115, SNU1040, HCT15, SW48, HCT116,
RKO, SNUC2A
3 CMS2-TGF-beta SW480
4 CMS4(mesenchymal) OUMS23, SNU503, NCIH716
5 CMS2-ErbB-Hippo-Wnt SW403, LS1034, SW620, SW1417
Cancer multiomics with deep learning Ronen et al. https://doi.org/10.26508/lsa.201900517 vol 2 | no 6 | e201900517 10 of 16
By including the cell lines predicted to be appropriate in the
clustering analysis, we also assigned them to specific CRC subtypes,
a finding which is likely to have far-reaching potential for drug
trials. One of the clusters (cluster 2, CMS1) consists mainly of
hypermutated tumors with low CIN, and the cell lines we matched
with that cluster using maui share their characteristics; such
matches have been a standard method in finding disease-specific
cell lines (41), and this shows that maui captures this characteristic.
We hope that our approach to predicting the fitness of cancer cell
lines as models for tumors can be verified and extended to other
cancer models, such as organoids and xenografts, in future ex-
periments. This could make maui indispensable for of drug dis-
covery pipelines and speed up new therapeutics.
The CRC subtypes we used as a starting point for this study had
previously been defined based solely on gene expression profiles. Our
aim to refine these subtype definitions using multiomics data restricted
us toa subset of the tumorsused in theCMSstudy.Weusedonly samples
from the TCGAwhich hadmeasurements for gene expression, mutations,
and copy numbers (n = 519). The original CMS study used a larger cohort
(n = 4,151). It is unclearwhether our proposal of splitting theCMS2 subtype
into two clusters would hold for a larger data set. Only when multiomics
data are available, this question will be possible to address.
Although the autoencoder architecture of maui is able to perform
inference in larger data at a fraction of the time required by matrix
factorization methods such as MOFA and iCluster+, it is more chal-
lenging to provide a biological interpretation of themodel it produces.
Linking genes to latent factors is not as straightforward as in matrix
factorization. The solution we propose is based on correlations be-
tween input genes and latent factor values, heuristically picking those
that are most significant. Although we were able to show that such
latent factors—gene relationships capture meaningful information
about cancer biology and recapitulate known associations between
the dysregulation of certain pathways and patient survival, this
method is potentially less robust in establishing these associations
and might require more user involvement in the analysis pipeline.
In this study, we have developed a deep learning–based mul-
tiomics integration method (maui) and shown that it can be used to
define clinically relevant subtypes of CRC, as well as predict the
fitness of cancer cell lines as models for the study of tumors. We
found new associations between cell lines and particular CRC
subtypes. The latent factors inferred bymaui are also interpretable in
a biological context and predictive of patient survival, which permits
associations to be made between underlying oncogenic processes
and patient survival. We benchmarked maui against two state-of-
the-artmethods formultiomics data integration and showed that not
only is it more effective in defining clinically meaningful subtypes
but also it does so with superior computational efficiency. An in-
crease in speed of orders of magnitude will permit maui to be used
in studies involving larger cohorts andmore types of omics data, an
experimental trend which will continue to increase in the future.
maui’s suitability as a general tool for multiomics integration
should also make it useful outside of the context of cancer to
explore issues related to in basic biology in studies using multiple
genomic assays.
Materials and Methods
Data
We obtained data for tumors from the TCGA-COAD (n = 389) and
TCGA-READ (n = 130) project designations of the Genomic Data
Commons (https://portal.gdc.cancer.gov) using the TCGAbiolinks R
package (42). We downloaded the CMS annotations for the TCGA
tumors from the Colorectal Cancer Subtyping Consortium (CRCSC)
(http://sagebionetworks.org/research-projects/colorectal-cancer-
subtyping-consortium-crcsc/). Table 1 summarizes the subtype
information. The gene expression data (mRNA) are HTSeq-FPKM. Mu-
tations were downloaded as mutation annotation files, filtered to
include nonsynonymous mutations only, and represented as a binary
mutation matrix where mij = 1 if and only if gene i carries a non-
synonymousmutation in sample j. Copy number alterations are GISTIC
calls by gene, represented as a real-valued matrix where cij is the
GISTIC segment mean for the segment containing gene i in sample j.
In addition, we obtained clinical metadata from the TCGA about
the same patients. In addition to survival data, we used the age at
diagnosis, sex, and tumor stage at diagnosis, as clinical covariates.
CCLE data were obtained from the CCLE portal (https://portals.
broadinstitute.org/ccle) and are the same data types as the TCGA
data, with the exception that transcriptome profiles are reads per
kilo base per million mapped reads (RPKM)-normalized and not
fragments per kilo base per million mapped reads (FPKM). We
considered 54 cancer cell lines originating from the colon.
We considered only tumors (from TCGA) and cancer cell lines
(from CCLE) which have “complete data”, that is, available mea-
surements in all three assays: gene expression, SNVs, and CNVs.
We used gene-wise median absolute deviation statistic, computed
directly on the raw data described above, to select the most infor-
mative genes. For the comparisons with MOFA and iCluster+, we used
the 1,000 genes with the highest median absolute deviation for gene
expression, 200 formutations, and 100 for copy number alterations, for
a total of 1,300 input features. We selected the features so strongly to
make a comparison against iCluster+ viable, and with a larger feature
space, the runtime would become untenable (Table 2).
For the final clustering analysis, we used a larger feature space,
with 5,000 gene expression values, 500 mutations, and 500 CNVs for
a total of 6,000 features, taking advantage of maui’s neural network
architecture which allows for larger feature spaces to undergo
feature selection as part of the training.
We fit the autoencoder using all TCGA samples, both with and
without a CMS label (n = 519, Table 1) as well as colon-derived
cancer cell lines (n = 54), for a total training set size of 573. For the
analysis that depends on a CMS label being available, the input
features were the latent factors and the samples only those TCGA
samples with a well-defined CMS label (n = 419, see Table 1).
All input features were scaled and centered before feeding to
the neural network, using batch normalization. Before this
scaling, mutation data were binary, CNV data GISTIC calls, and gene
expression counts were RPKM/FPKM values which were scaled and
centered. TCGA and CCLE gene expressionmatrices were first scaled
and centered individually and, then, concatenated and scaled
jointly to filter out the “batch effect” of CCLE versus TCGA data
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enable mapping of tumors and cell lines to the same space. This
means that for a trained maui model, when new, unseen samples
are to be mapped onto the latent factor space, they must first be
normalized in this way to fit the distribution of the training data.
Network-smoothing of multiomics data
We applied netSmooth (27) to the binary mutation matrix before
feeding it into the neural network of maui. Themethod uses the PPI to
smooth noisymolecular assays in effect, incorporating prior data from
countless previous experiments, to improve the signal-to-noise-ratio.
The intuition behind the method is that genes seldom act alone, and
genes in close neighborhoods in the PPI are expected to behave
similarly. For instance, interacting proteins tend to be coexpressed
(43), and somatic mutations or amplifications/deletions in interacting
may lead to similar dysfunctions. We used α = 0.7, a rule-of-thumb for
network smoothing mutations (26).
The algorithm is a simple Random Walks with Restarts diffusion
process on the PPI, described by the iterative process
Ft+1 = αAFt + ð1 −αÞF0;
where F is a data matrix (gene expression, mutations, etc.), A is the
degree-normalized adjacency matrix of the PPI, and (1 − α) is the
restart rate. The process is guaranteed to converge and has a
closed-form solution
F∞ = ðI −αAÞ−1F0:
To pick the optimal α value, we performed a grid search over a
range between 0 and 1, and picked the lowest α value within 1 SD of
the highest score on the Harrell’s c-index benchmark (Fig 1E–G).
Latent factor model for multiomics data
Starting from different data matrices xi from different modalities,
we call the full multiomics data set x = ½x1; x2; :::; xm.
We define a generative model x e p xjzð Þ. Graphically, our model
looks like Fig 7A, a Bayesian latent variable model where the
variation in the data x are explained by the variation in a smaller set
of latent factors, z. To infer the latent variables z ep zjxð Þ, as p zjxð Þ is
generally intractable, we proceed with a variational Bayes framework,
that is, approximating p zjxð Þ ≈ qθ zjxð Þ, where qθ zjxð Þ is a simple
class of distribution, and minimizing the Kullback–Leibler (KL) di-
vergence DKL qθ zjxð Þ k p zjxð Þð Þ. This is equivalent to maximizing the
evidence lower bound (44):
ELBO = Eq log pϕ xjzð Þ
  
−DKL qθ zjxð Þ k pϕ zð Þ
 
:
In the equation above, log pϕ xjzð Þ
 
is the log-likelihood of the
reconstruction, so that its expectation under the encoder, the first
term Eq log pϕ xjzð Þ
  
is the cross-entropy loss of the reconstruction.
Thus, the second term (KL divergence) can be seen as a regularizer on
the latent factors.
We follow (16 Preprint) and reparameterize zli as
zli = μi + σiϵl
where
ϵl ~Nð0; IÞ;
which allows us to construct the autoencoder shown in Fig 7B.
The first half of the autoencoder, leading from x to z (the “en-
coder”), is a neural network which will be trained to compute
qθðzvxÞ, that is, θ denotes the weights of the encoder network. The
second half, the “decoder” network, is a neural network which will be
trained to compute pϕðzvxÞ, so ϕ denotes the weights of the decoder
network. Thanks to the reparametrization of z, the path from x to
x^ is differentiable, via backpropagation, in θ and ϕ, and thus, we can
use gradient descent to optimize a loss function that is differen-
tiable in θ and ϕ.
Setting the loss function of the neural network to the negative
evidence lower bound
l = −Eq log pϕ xjzð Þ
  
+DKL qθ zjxð Þ k pϕ zð Þ
 
;
we see that the first term is equivalent to the cross-entropy re-
construction loss, and the second term, the KL-divergence between
qθ zjxð Þ and the prior pϕðzÞ can be seen as a regularization term, will
push the z’s to their prior distribution.
Stacking autoencoders
The VAE described above is for a one-layer Bayesian framework,
that is, Fig 7A. But autoencoders may be stacked (45) to produce
deeper neural network architectures. Deep architectures have more
than one layer of nonlinearities and can, thus, more compactly
capture highly nonlinear functions. We introduce a hidden layer to
our Bayesian latent variable model (Fig 7C).
Figure 7. Variational autoencoder. (A) Plate model of latent factor model; x ~ pðzjxÞ.
(B) Visual representation of the VAE. (C) Plate model of the stacked latent factor
model. (D) Visual representation of the stacked variational autoencoder.
Cancer multiomics with deep learning Ronen et al. https://doi.org/10.26508/lsa.201900517 vol 2 | no 6 | e201900517 12 of 16
Using the reparametrization trick as above and specifying the full
loss function, inference in the generative model (Fig 7C can be
performed by backpropagation in the stacked VAE model (Fig 7D).
Model regularization
Deep neural networks have many parameters, making them very
flexible. This flexibility, however, comes at a cost—deep models are
prone to overfitting: the generation of models which explain the
training data well, but generalize poorly to new data. In addition,
deep nets are prone to producing complex relationships between
many variables. In the case of a latent variable model, that means
latent factors that change with the variation of any of a large number
of input features, a property which makes the task of interpreting the
biological meaning of those latent factors difficult. In technical terms,
we wish to enforce sparsity in qθ zjxð Þ so that each latent factor will
depend on fewer of the inputs.
To address the first issue of potential overfitting, we used batch
normalization (46). When fitting the model, we segmented the
data into minibatches, at each iteration computing derivatives
and making updates to the model based on that sample. Using
batch normalization, each feature is scaled and centered in each
minibatch. We fed all of the training examples to the model fitting
procedure until the entire training set is exhausted, and then, we
segmented it into new minibatches and repeated the process, for
a specified number of epochs. This way, each time a training
sample is passed to the model, it will be slightly different, which is
roughly equivalent to adding noise, which has been shown to work
as a regularizer in denoising autoencoders (47) and prevent
overfitting. Furthermore, batch normalization addresses another
issue—that of internal covariate shift. Internal covariate shift happens
when the distributions of activations of internal nodes in the neural
network change while training. Reducing internal covariate shift en-
ables us to pick higher learning rates and, thus, speeds up inference
considerably.
The second mode of regularization, encouraging representa-
tions, where latent factors depend only on a few input features, is
partially achieved by the KL term in the loss function, as that
penalizes distributions of z’s which are far from the Gaussian
prior. Disentangled representations, where latent factors depend
on complementary input feature sets, can support this kind of
sparsity. This holds when latent factor representations are non-
negative, which we achieve by passing them through a rectified
linear unit (ReLU). When each non-negative latent factor de-
pends on a different set of inputs, the relationships will be
sparser.
We, therefore, add a multiplier to the loss function similar to
β-VAE (18) and, allowing us to weigh the relative importance of the
terms:
l = −Eq log pϕ xjzð Þ
  
+βDKL qθ zjxð Þ k pϕ zð Þ
 
To ensure the network finds a good representation before it
starts regularizing, we used the “warm-up”method proposed by (17
Preprint), where β is initially 0 and is gradually increased by β = β + κ
until its value reaches 1.
Model selection
The stacked VAE presented above is a class of models which are
parameterized by the number of hidden units (the dimensionality
of h), Nhidden, and the number of latent factors, Nlatent.
This presents an opportunity for selecting the best model by
spanning a grid over the two parameters and computing some
scores. We searched the space spanned by (Nhidden, Nlatent) and
computed a compound benchmark score at each point. The
compound benchmark score is the average of the scores of the AUC
in the supervised CMS prediction task, the AMI in the unsupervised
CMS subtype prediction task, the −log10p of the multivariate log-
rank test for differential survival statistics, and the c-index (25) from
the Cox proportional hazards model. maui is largely insensitive to
the choice of (Nhidden, Nlatent), for Nlatent > 30 (Fig S10).
MOFA was run using the default parameters. It uses heuristics to pick
the number of latent variables, startingwith a largenumber andpruning
away ones with an explained variance ratio of beneath a threshold of
2%. The resulting model had 20 components. To see if MOFA’s heuristic
picks a sensible model, we also ran it with fixed numbers of latent
factors over a range from 10 to 30 and computed the composite
benchmark, lower than for maui because of the higher runtime.
For iCluster+, there are two free parameters: the regularization
parameter λ and the number of latent factors. We ran a grid search
over the regularization parameter and number of latent variables
space, similar to the way maui was tuned, but with a lower number
of maximum latent factors because of iCluster+’s prohibitive runtime
for larger numbers. For each parameter configuration, we computed
the compound benchmark. maui consistently outperforms both MOFA
and iCluster+ for most parameter sets (Fig S11).
For the final analyses shown in the results section, to avoid
leakage of benchmarks into the unsupervised learning algorithms,
we ran maui with parameters corresponding the mean of the distri-
bution of compound benchmarks (Nhidden = 1,100 and Nlatent = 100); the
same reasoning for iCluster+ resulted in five latent factors. We allowed
MOFA to use its own heuristic, discarding latent factors with variance
explained below 2%, yielding a 20-component model. We used the
MOFA default threshold when picking the number of components to
keep in the PCA comparison, which yielded five components.
Model implementation
We implemented the model using Keras (v2.1.5) using a TensorFlow
(v1.6.0) backend. We used rectified linear units for all activations
except for the last layer which is sigmoids, for all features. We
trained our network for 600 epochs using minibatches of size 100
and κ = 0.01. We used the Adam optimizer (48).
Predicting CMS from latent factors using SVM
To quantify the correspondence between latent factors learned by
using different methods and the CMS label, we used SVMs (49), a
supervised learning algorithm. There were two levels of CV; first, we
split the whole data set into 10 folds, reserving at each time 10% of
the data set as a test set. At each round, we trained the latent factor
models (maui, iCluster+, and MOFA) and the SVM predictor on 90%
of the data and used that model to assign a CMS subtype to the
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remaining 10%. Within each CV fold, we used regularized SVM to
predict the CMS from the latent factors. The regularization pa-
rameter of the SVM was picked using another 10-fold CV, splitting
the “outer” 90% training data into “inner” ninety 10 splits. ROC
curves were computed for each class bymodeling a binary outcome
for each CMS label (one-versus-all). Mean ROC curves were com-
puted by averaging the ROC of all CMS labels at each point.
Unsupervised prediction of CMS from latent factors using
k-means clustering
We benchmarked maui against MOFA and iCluster+ in the power of
latent factors to predict CMS labels in an unsupervised fashion to
present a fair comparison betweenmaui (70 latent factors) andMOFA
(20 latent factors) and iCluster+ (10 latent factors). We used k-means
clustering, as clustering based on distance metrics suffers from the
“curse of dimensionality,” and does not, in general, benefit from a
larger number of input dimensions (unlike supervised learning
methods). To assess the ability of k-means clusters to capture the
CMS labels, we ran k-means with 1,000 starts, picking the best
(lowest variance) solution for each run. In addition, we applied the
algorithm with K’s in the range of 2–9. For the cluster assignments for
each K, we computed AMI of the clusteringwith the CMS labels. The AMI
is an information-theoretic measure of the concordance between two
labelings (clusterings and CMS), which accounts for chance. Higher
values indicate closer relationships between labelings.
A novel subtyping scheme for CRC with cell line associations to
subtypes
The subtyping scheme presented in the results section is based on
k-means clustering using maui latent factors learned from mul-
tiomics data. We did this using a maui model trained on 6,000 input
features (5,000 gene expression, 500 mutation, and 500 CNV), as it is
more predictive of patient survival than the one using 1,300 features
(Fig 1F) and produces largely the same cluster assignments as the
1,300 gene model presented above (Fig S12).
Association of latent factors with genomic features
The stacked variational autoencoder model described above com-
putes latent factors z = f(x), where f(x) is a nonlinear function which
may not necessarily be well approximated by a linear z ≈ Wx, as in
models such as MOFA or iCluster+. The architecture and depth of the
neural network also makes it nontrivial to associate the input ge-
nomic features (gene expression, mutations, etc.) with the different
latent factors. However, to make biological sense of the latent
factors, it is necessary to make that association. To do that, we
computed Spearman’s ρ for each latent factor with each input
feature and called a latent factor associated with an input feature if
P < 0.001.
Gene set enrichment
To identify genes associated with the different clusters, we performed a
differential expression analysis using t tests and Benjamini–Hochberg
correction for multiple hypothesis testing. Genes with adjusted P
value below 0.05 were called differentially expressed. To find out if
the genes associated with latent factors (Fig 3) or with clusters (Fig
2) belong to known pathways, we used Enrichr (50, 51) via the
python package gseapy (version 0.9.4, available from PyPI https://
pypi.org/project/gseapy). We used pathways (gene sets) defined
by the Kyoto Encyclopedia of Genes and Genomes (52, 53, 54).
Survival analysis
We relied on overall survival data from the TCGA annotations for all
survival analyses.
To assess the prognostic value of latent factors inferred by our
deep learning approach, we fit a Cox proportional hazardsmodel (29),
ln h tð Þho tð Þ = i βixi;
where the left hand side is the logarithm of the hazard ratio and x’s
are covariates. We assessed the predictive value of each latent
factor separately, while controlling for the patient’s age, gender,
and tumor stage at diagnosis. We computed confidence intervals
for the coefficient β associated with the latent factor and picked the
latent factors with false discovery rate-correction and α = 0.95.
To compare the prognostic value of different models, we com-
puted the c-index (55, 56, 57) and used 5-fold CV (49).
The log-rank statistics reported in Figs 1D and S3 are multivariate
log-rank test, under the null hypothesis that all groups have the
same survival function, with an alternative hypothesis that at least
one group has a different survival function.
All survival analysis was performed using the python package
lifelines (https://lifelines.readthedocs.io/en/latest/).
Comparing models’ survival-predictive value
To compare maui to MOFA and iCluster+ (as well as to a gene
expression only–based maui model), we used Harrell’s C (25) in a
Cox proportional hazards (29) regression model. The c-index was
computed for Cox models based only on clinically relevant factors,
which we selected using individual, unregularized Cox models, one
per factor, while controlling for patient age, sex, and tumor stage. In
those individual factor models, we used Efron’s method to compute
confidence intervals and only to keep the latent factors with sta-
tistically significant (adjusted P-value 0.05) nonzero coefficients in
the individual Cox models. Having selected clinically relevant latent
factors from each model (maui, MOFA, iCluster+, maui-expression,
and maui-netsmooth), we fitted a full Cox regression using those
2and ran a cross-validated out-of-sample c-index calculation using
regularized Cox PH regression, searching for the optimal result
among the regularizers 1, 10, 100, 1000, 10000. The results re-
ported in Fig 1F are the best-regularized model for each of the
methods.
Quality assessment of CRC cell lines for modeling tumors
To assess the fitness of different cancer cell lines as models for
tumors, we computed the pairwise Euclidean distance between
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each of the samples (TCGA and CCLE), in the space of the latent
factors derived from maui. Then, we computed, for each cell line, the
proportion of its five nearest neighbors which are also cell lines, the
working hypothesis being that cell lines that form “cell line clusters”
are more cell-line like than tumor like, and likely less fit as models for
tumors. We repeated the exercise considering other numbers of
nearest neighbors from 1 to 20, at each K computing the true positive
rate (recall), that is, No:of noncolon cell lines predicted to be poormodelsNo: of noncolon cell lines , showing
that the recall is near perfect for a wide range of K’s.
Software
maui is available as a general purpose python package for the study
of multiomics data. For more information, visit https://github.com/
BIMSBbioinfo/maui.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900517.
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